A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
Phase 1
4–12
6 sites in CA, FL, LA +2
What this study is about
This Phase 1 study is testing Budesonide in people with asthma. The primary outcome being measured is Maximum observed plasma concentration (Cmax).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
budesonide, Respiratory System Agent (Adrenergic beta2-Agonists)
oral (Delayed Release Oral Capsule)
Primary: Maximum observed plasma concentration (Cmax)
Secondary: Apparent total body clearance (CL/F), Number of participants with adverse events, Terminal elimination half-life (t½λz), Time to reach peak or maximum observed concentration or response following drug administration (tmax)
Respiratory